Economic Impact of Imatinib Mesylate Withdraw: An Option for Third World Countries?
نویسندگان
چکیده
منابع مشابه
Clinical pharmacokinetics of imatinib mesylate.
This review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.
متن کاملImatinib mesylate: A designer drug.
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positiv...
متن کاملImatinib mesylate in polycythemia vera
In the September 15, 2003, issue of Blood,1 Oehler et al describe imatinib mesylate inhibition of the autonomous in vitro proliferation of peripheral blood– and bone marrow–derived polycythemia vera (PV) erythroid burst-forming units (BFU-Es). While their results superficially correlate with the previously published in vivo clinical observations of Silver,2 the conclusions of Oehler et al are a...
متن کاملImatinib mesylate induced skin hypopigmentation.
Sir, Imatinib mesylate is a tyrosine kinase inhibitor that targets BCR-ABL protein in chronic myelogenous leukemia (CML).1 We present three cases of CML, treated with Imatinib who developed clinical findings of hypopigmentation. All the three patients noticed pigmentation changes after the initiation of therapy with Imatinib mesylate, which was persistent during therapy. The presence of hypopig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2015
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v126.23.5161.5161